文献速递泌尿生殖与妇科肿瘤放疗

剂量递增外照射放疗后PSA闪烁是前列腺腺癌PSA复发、转移和生存的独立预测因素

Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-10-13

研究纳入1990-2010年接受剂量递增外照射放疗(DE-EBRT)至≥75 Gy且随访≥5年的1898例前列腺腺癌患者,排除接受新辅助/同期雄激素剥夺治疗或放疗后6个月以上PSA值少于4次者,最终分析776例(中位剂量81.0 Gy)。多因素分析显示PSA-B与PSA复发风险降低(HR 0.53;95%CI 0.33-0.85;P=.008)、远处转移风险降低(HR 0.34;95%CI 0.12-0.94;P=.04)和全因死亡风险降低(HR 0.53;95%CI 0.29-0.96;P=.04)独立相关,且PSA-B患者癌症特异性生存优于无PSA-B者(P=.004)。

要点

  • DE-EBRT后PSA闪烁(≥0.2 ng/mL升高后回落至nadir或以下)发生率为15.9%,中位24.6个月。
  • PSA闪烁独立预测PSA复发、远处转移和全因死亡风险降低。
  • PSA闪烁患者癌症特异性生存优于无闪烁者(P=.004)。

核心结论

  • 接受剂量递增放疗的前列腺腺癌患者出现治疗后PSA闪烁者,其PSA无复发生存、无远处转移生存、总生存和癌症特异性生存均更优。

研究设计与样本

  • 回顾性队列研究,1990-2010年1898例前列腺腺癌患者接受DE-EBRT至≥75 Gy且随访≥5年。
  • 排除接受新辅助/同期雄激素剥夺治疗者(n=1035)及放疗后6个月以上PSA值少于4次者(n=87),最终分析776例,中位剂量81.0 Gy,中位随访9.2年(四分位距6.9-11.3年)。

主要发现

  • 多因素分析显示较年轻年龄(P=.001)、较低Gleason评分(P=.0003)和较高放疗剂量(P=.0002)独立预测PSA闪烁。
  • 多因素Cox分析显示PSA闪烁与PSA复发风险降低(HR 0.53;95%CI 0.33-0.85;P=.008)、远处转移风险降低(HR 0.34;95%CI 0.12-0.94;P=.04)和全因死亡风险降低(HR 0.53;95%CI 0.29-0.96;P=.04)独立相关。
  • 无PSA闪烁患者中全部50例前列腺癌特异性死亡均发生于非闪烁队列,竞争风险分析不适用;非参数竞争风险检验显示PSA闪烁患者癌症特异性生存优于无闪烁者(P=.004)。

关键数值与推荐

  • PSA闪烁定义为PSA较区间最低值升高≥0.2 ng/mL后下降至最低值或以下。
  • PSA复发定义为放疗后PSA最低值+2 ng/mL。

临床怎么用

  • 对于接受剂量递增外照射放疗的前列腺腺癌患者,治疗后出现PSA闪烁(≥0.2 ng/mL升高后回落)可能提示较好的预后,包括PSA复发、远处转移和死亡风险降低。
  • 临床随访中识别PSA闪烁有助于避免对良性PSA波动进行过度干预。

局限性

  • 研究为回顾性设计,排除了接受雄激素剥夺治疗及PSA监测不足的患者,可能影响结果的外推性。
  • 无PSA闪烁患者中前列腺癌特异性死亡事件全部集中于非闪烁队列,导致竞争风险分析不适用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the difference in prostate-specific antigen (PSA) recurrence-free, distant metastasis-free, overall, and cancer-specific survival between PSA bounce (PSA-B) and non-bounce patients treated with dose-escalated external beam radiation therapy (DE-EBRT). METHODS AND MATERIALS: During 1990-2010, 1898 prostate adenocarcinoma patients were treated with DE-EBRT to ≥75 Gy with ≥5 years follow-up. Patients receiving neoadjuvant/concurrent androgen-deprivation therapy (n=1035) or with fewer than 4 PSA values obtained 6 months or more after post-EBRT completion (n=87) were excluded. The evaluable 776 patients were treated (median, 81.0 Gy). Prostate-specific antigen bounce was defined as a ≥0.2-ng/mL increase above the interval PSA nadir, followed by a decrease to nadir or below. Prostate-specific antigen relapse was defined as post-radiation therapy PSA nadir + 2 ng/mL. Median follow-up was 9.2 years (interquartile range, 6.9-11.3 years). RESULTS: One hundred twenty-three patients (15.9%) experienced PSA-B after DE-EBRT at a median of 24.6 months (interquartile range, 16.1-38.5 months). On multivariate analysis, younger age (P=.001), lower Gleason score (P=.0003), and higher radiation therapy dose (P=.0002) independently predicted PSA-B. Prostate-specific antigen bounce was independently associated with decreased risk for PSA relapse (hazard ratio [HR] 0.53; 95% confidence interval [CI] 0.33-0.85; P=.008), distant metastatic disease (HR 0.34; 95% CI 0.12-0.94; P=.04), and all-cause mortality (HR 0.53; 95% CI 0.29-0.96; P=.04) on multivariate Cox analysis. Because all 50 prostate cancer-specific deaths in patients without PSA-B were in the non-bounce cohort, competing-risks analysis was not applicable. A nonparametric competing-risks test demonstrated that patients with PSA-B had superior cancer-specific survival compared with patients without PSA-B (P=.004). CONCLUSIONS: Patients treated with dose-escalated radiation therapy for prostate adenocarcinoma who experience posttreatment PSA-B have improved PSA recurrence-free survival, distant metastasis-free survival, overall survival, and cancer-specific survival outcomes.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Romesser PB, Pei X, Shi W, et al. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. Int J Radiat Oncol Biol Phys. 2017. PMID: 29254782. doi:10.1016/j.ijrobp.2017.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。